T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia

References

• Acheampong DO, Adokoh CK, Asante DB, et al. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Biomed Pharmacother. 2018;97:225–232. doi:10.1016/j.biopha.2017.10.10029091870
   PubMed Web of Science ®Google Scholar
• Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018;2(11):1356–1366. doi:10.1182/bloodadvances.201801637829895626
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050.7655033
   PubMed Web of Science ®Google Scholar
• Toprak SK. Donor lymphocyte infusion in myeloid disorders. Transfus Apher Sci. 2018;57(2):178–186. doi:10.1016/j.transci.2018.04.01829754984
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010;107(31):13824–13829. doi:10.1073/pnas.100805110720631300
   PubMed Web of Science ®Google Scholar
• Anguille S, Van de Velde AL, Smits EL, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017;130(15):1713–1721. doi:10.1182/blood-2017-04-78015528830889
   PubMed Web of Science ®Google Scholar
• Weber G, Gerdemann U, Caruana I, et al. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. 2013;27:1538–1547. doi:10.1038/leu.2013.6623528871
   PubMed Web of Science ®Google Scholar
• Lulla P, Naik S, Tzannou I, et al. Safety and efficacy of adoptively transferred donor-derived tumor-directed T cells with relapsed AML post-allogeneic HSCT. Blood. 2017;130:164.
   Web of Science ®Google Scholar
• Leen A, Tzannou I, Bilgi M, et al. Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens. Blood. 2015;126:186.
   Web of Science ®Google Scholar
• Zhang Q, Liu X, Wang XB, et al. Amplification ex Vivo and cytocidal activity of leukemia tumor-associated antigen-specific cytotoxic T lymphocytes. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(3):814–820. doi:10.7534/j.issn.1009-2137.2015.03.04126117042
   PubMedGoogle Scholar
• Cruz CR, Bollard CM. Adoptive immunotherapy for leukemia with ex vivo expanded T cells. Curr Drug Targets. 2017;18(3):271–280. doi:10.2174/138945011766616020914352926648070
   PubMed Web of Science ®Google Scholar
• Bollard CM, Tripic T, Cruz CR, et al. Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma. J Clin Oncol. 2018;36(11):1128–1139. doi:10.1200/JCO.2017.74.317929315015
   PubMed Web of Science ®Google Scholar
• Martínez A, Olarte I, Mergold MA, et al. mRNA expression of MAGE-A3 gene in leukemia cells. Leuk Res. 2007;31(1):33–37. doi:10.1016/j.leukres.2006.05.00916806467
   PubMed Web of Science ®Google Scholar
• Greiner J, Ringhoffer M, Simikopinko O, et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol. 2000;28(12):1413–1422.11146163
   PubMed Web of Science ®Google Scholar
• Greiner J, Bullinger L, Guinn BA, Döhner H, Schmitt M. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res. 2008;14(22):7161–7166. doi:10.1158/1078-0432.CCR-08-110219010831
   PubMed Web of Science ®Google Scholar
• Maslak PG, Dao T, Krug LM, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010;116:171–179. doi:10.1182/blood-2009-10-25099320400682
   PubMed Web of Science ®Google Scholar
• Matko S, Manderla J, Bonsack M, et al. PRAME peptide-specific CD8+ T cells represent the predominant response against leukemia-associated antigens in healthy individuals. Eur J Immunol. 2018;48(8):1400–1411. doi:10.1002/eji.20174739929738081
   PubMed Web of Science ®Google Scholar
• Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol. 2013;31:137–161. doi:10.1146/annurev-immunol-032712-09595423215646
   PubMed Web of Science ®Google Scholar
• Schluns KS, Lefrançois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003;3(4):269–279. doi:10.1038/nri105212669018
   PubMed Web of Science ®Google Scholar
• Shmarov VA, Malashchenko VV, Meniailo ME, et al. Direct effects of interleukin-7 on the function of human T cells in vitro. Eur Cytokine Netw. 2016;27(4):102–107. doi:10.1684/ecn.2016.038528396296
   PubMed Web of Science ®Google Scholar
• Mueller YM, Makar V, Bojczuk PM, Witek J, Katsikis PD. IL-15 enhances the function and inhibits CD95/Fas-induced apoptosis of human CD4+ and CD8+ effector-memory T cells. Int Immunol. 2003;15(1):49–58. doi:10.1093/intimm/dxg01312502725
   PubMed Web of Science ®Google Scholar
• Sato N, Patel HJ, Waldmann TA, Tagaya Y. The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci U S A. 2007;104(2):588–593. doi:10.1073/pnas.061011510417202253
   PubMed Web of Science ®Google Scholar
• Mehrotra PT, Grant AJ, Siegel JP. Synergistic effects of IL-7 and IL-12 on human T cell activation. J Immunol. 1995;154(10):5093–5102.7730615
   PubMed Web of Science ®Google Scholar
• van Luijn MM, Chamuleau ME, Thompson JA, et al. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica. 2010;95(3):485–493. doi:10.3324/haematol.2009.01059519903675
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Luetkens T, Kloth B, et al. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol. 2011;86(11):918–922. doi:10.1002/ajh.2214121898529
   PubMed Web of Science ®Google Scholar
• Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, et al. The DNA demethylating agent 5-aza-2ʹ-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 2010;34(7):899–905. doi:10.1016/j.leukres.2010.02.00420381863
   PubMed Web of Science ®Google Scholar
• Srivastava P, Paluch BE, Matsuzaki J, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7(11):12840–12856. doi:10.18632/oncotarget.732626883197
   PubMedGoogle Scholar
• Griffiths EA, Srivastava P, Matsuzaki J, et al. NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome. Clin Cancer Res. 2018;24(5):1019–1029. doi:10.1158/1078-0432.CCR-17-179228947565
   PubMed Web of Science ®Google Scholar